Skip to main content
Premium Trial:

Request an Annual Quote

CDC Will Develop Bacterial Assays With Nanogen System

NEW YORK, June 6-Nanogen said today that it will work with the U.S. Centers for Disease Control to adapt its chip-based system to detection of diarrheal Escherichia coli and other pathogens.


Nanogen will install one of its NanoChip workstations at the CDC's Foodborne and Diarrheal Diseases Branch in Atlanta, Ga. Under a "Development Site Agreement," CDC researchers will have preferential access to Nanogen technology as they develop assays for particular strains of pathogenic bacteria.


Nanogen receives licensing and commercialization rights to these assays, and may use this research to develop other diagnostic tests.


At the end of the program, the CDC will have an option to purchase the Nanogen system.


For more details, see the press release.



The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.